Literature DB >> 17970091

Antineoplastic activity of a series of ferrocene-containing alcohols.

Rebotsamang F Shago1, Jannie C Swarts, Elke Kreft, Constance E J Van Rensburg.   

Abstract

BACKGROUND: Often potentially good chemotherapeutic drugs find limited clinical use due to the many negative medical and physical side-effects they may exhibit. To combat these negative side-effects, new antineoplastic materials are continuously being synthesised and evaluated. Ferrocene-containing compounds under certain conditions may show appreciable anticancer activity. Some of the factors that determine this activity have been investigated.
MATERIALS AND METHODS: Ferrocene-containing alcohols were tested for cytotoxicity against the HeLa cancer cell line. Cell survival was measured by means of the colorometric 3-(4,5-dimethylthiazol-2-yl)-diphenyltetrazolium bromide assay.
RESULTS: The 50% lethal dosage of 4-ferrocenylbutanol was 5.72 micromol. dm(-3) and for 2-ferrocenylethanol and 3-ferrocenylpropanol it was 35.0 and 17 micromol. dm(-3) respectively while for ferrocenylmethanol IC50 was >100 micromol. dm(-3).
CONCLUSION: A drug activity-structural relationship exists in that ferrocenyl drugs with longer side chains are more cytotoxic. Compounds with lower ferrocenyl group formal reduction potential are also more cytotoxic.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17970091

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  2 in total

1.  Synthesis, Spectroscopy, Electrochemistry and DFT of Electron-Rich Ferrocenylsubphthalocyanines.

Authors:  Pieter J Swarts; Jeanet Conradie
Journal:  Molecules       Date:  2020-06-01       Impact factor: 4.411

2.  Physicochemical characterization and cytotoxic activity evaluation of hydroxymethylferrocene:β-cyclodextrin inclusion complex.

Authors:  Rosa Iacovino; Jolanda Valentina Caso; Filomena Rapuano; Agostino Russo; Marina Isidori; Margherita Lavorgna; Gaetano Malgieri; Carla Isernia
Journal:  Molecules       Date:  2012-05-21       Impact factor: 4.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.